Purple Biotech Ltd. (PPBT)
PPBT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1614744/000121390023017024/0001213900-23-017024-index.htm. Net income: SEC 20-F (us-gaap:ProfitLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PPBT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2015 |
| SEC CIK | 0001614744 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $1.0M |
| Net income | $28.7M |
| Operating income | -$12.6M |
| Net margin | 2870.1% |
| Operating margin | -1261.2% |
| Revenue growth | 0.0% |
| Cash | $11.2M |
| Total assets | $83.8M |
| P/E (computed) | 0.1× |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-19 |
| Cash and burn | $8.7M cash; operating cash flow -$1.4M a quarter. | Report 2025-12-31 |
| Shares outstanding | 929,456 (2025-12-31); 258,564 a year earlier; 92,408 three years earlier. 1y figure adjusted for splits (1-for-10 overall); 3y figure adjusted for splits (1-for-200 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-10 on 2026-03-02 | Source 2026-03-02 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Somekh Chaikin, Tel Aviv, Israel | PCAOB Form AP 2026-04-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 1,626,867 shares at the 2026-11-13 price; the latest SEC cover count is 929,456 as of 2025-12-31. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$26.4M | -$5.7M | $8.7M | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2024 2024-12-31 | Not filed | -$7.2M | -$14.4M | $7.4M | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2023 2023-12-31 | Not filed | -$19.9M | -$19.9M | $14.5M | No debt tags | Needs four quarters | 20-F 2026-03-19 |
| FY 2022 2022-12-31 | Not filed | -$21.7M | -$16.7M | $15.0M | No debt tags | Needs four quarters | 20-F 2025-03-10 |
| FY 2021 2021-12-31 | Not filed | $17.8M | -$374K | $10.9M | No debt tags | Needs four quarters | 20-F 2022-03-09 |
| FY 2020 2020-12-31 | $1.0M | $28.7M | $1.7M | $11.2M | No debt tags | $1.0M | 20-F 2023-03-03 |
| FY 2019 2019-12-31 | $1.0M | $5.4M | -$2.0M | $4.4M | No debt tags | $1.0M | 20-F 2021-03-16 |
| FY 2018 2018-12-31 | $1.0M | $5.2M | -$8.5M | $5.2M | No debt tags | $1.0M | 20-F 2021-03-16 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | F-3 | 2026-05-20 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-03-19 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-10-05 |
Source: SEC EDGAR submissions feed, 580 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +24.4% |
| 1 month | +19.9% |
| 3 months | +9.0% |
| Year to date | -75.2% |
| 1 year | -78.0% |
| From 52-week high | -81.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EOCN | Eocene Ltd. | $2.53 | +5.86% | $2.6M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier